A case report: retigabine induced oral mucosal dyspigmentation of the hard palate

BMC Oral Health

Christine Goodall¹  Martin J. Brodie³  Nicholas G. Beacher² 

[1] Oral Surgery and Sedation. University of Glasgow Dental School, School of Medicine, College of Medical, Veterinary & Life Sciences, Glasgow, UK;Special Care Dentistry, University of Glasgow Dental School, School of Medicine, College of Medical, Veterinary & Life Sciences, 378, Sauchiehall Street, Glasgow G2 3JZ, UK;Medicine and Clinical Pharmacology, Western Infirmary, Epilepsy Unit, Western Infirmary, Glasgow, UK

关键词: Oral mucosal dyspigmentation;    Retigabine;   

Others  :  1228297
DOI  :  10.1186/s12903-015-0102-y

 received in 2015-04-22, accepted in 2015-10-05,  发布年份 2015

【 摘 要 】

Background

Dyspigmentation of the oral mucosa has a multitude of aetiological causes. Retigabine, a new antiepileptic drug, has the potential side effect of inducing a blue/purple pigmentation of the oral mucosa in addition to the skin, lips, nails and retina of the eyes. This article presents a unique case of dyspigmentation present in the oral mucosa of the hard palate which has previously been unreported in the dental literature.

Case presentation

A 70 year old white male presented to a secondary care oral surgery department with an unusual asymptomatic pigmented lesion present in the hard palate of the oral cavity. The pigmentation was remarkable for its distinct blue/purple colouration which was associated with a similar discolouration of the nail beds of the hands. This is believed to be a side effect of the anti-epileptic medication retigabine.

Conclusion

The dental profession and wider healthcare community should be made fully aware of the potential side effect of oral dyspigmentation associated with the novel anti-epileptic medication retigabine. Enhanced knowledge of the causative role of retigabine in dyspigementation of the oral mucosa will allow the practitioner to make an appropriate diagnosis. As far the authors are aware this is reaction is unreported in the dental literature and should be disseminated to the wider oral health professional’s community.

【 授权许可】

   
2015 Beacher et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G et al.. Definition of drug-resistant epilepsy: conscensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010; 51:1069-77.
• [2]Bell G, Neligan A, Sander J. An unknown quantity – the worldwide prevalence of epilepsy. Epilepsia. 2014; 55:958-62.
• [3]Wright J, Pickard N, Whitfield A, Hakin N. A population-based study of the prevalence, clinical characteristics and effect of ethnicity in epilepsy. Seizure. 2000; 9:309-13.
• [4]Brodie MJ, Barry SJE, Bamagous GA, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012; 78:1548-54.
• [5]Villanueva V, Girón JM, Martín J, Hernández-Pastor LJ, Lahuerta J, Doz M et al.. Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study. Neurologia. 2013; 28(4):195-204.
• [6]Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P et al.. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010; 75(20):1817-24.
• [7]French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S et al.. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011; 76(18):1555-63.
• [8]European Medicines Agency. 2011. CHMP Assessment Report; retigabine. Procedure No.EMEA/H/C/001245. EMA London. 20 January 2011. http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/001245/WC500104839.pdf. webcite
• [9]Tompson DJ, Crean CS, Reeve R, Berry NS. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures. Clin Ther. 2013; 35(8):1174-85.
• [10]F.D.A.2013. FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. FDA, Maryland. 26 April 2013. http://www. fda.gov/Drugs/DrugSafety/ucm372774.htm. webcite
• [11]Shkolnik TG, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L et al.. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014; 150(9):984-9.
• [12]Huber B, Bocchicchio M. A retrospective evaluation of retigabine in patients with high therapy-resistant epilepsy. Epilepsy and Behavior, in press.
• [13]Alawi F. Lesions of the oral cavity: an update. Dent Clin North America. 2013; 57(4):699-710.
• [14]Akintoye SO, Boyce AM, Collins MT. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116(3):10.1016.
• [15]Nieman L. Cushing’s: Update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015; 173(4):M33-8.
• [16]Brandão Neto RA, de Carvalho JF. Diagnosis and classification of Addison’s disease (autoimmune adrenalitis). Autoimmun Rev. 2014; 13(4–5):408-11.
• [17]Feller L, Masilana A, Khammissa RAG M, Jadwat Y, Lemmer J. Melanin: the biophysiology of oral melanocytes and physiological oral pigmentation. Head Face Med. 2014; 10:8. BioMed Central Full Text
• [18]Müller S. Melanin-associated pigmented lesions of the oral mucosa: presentation, differential diagnosis, and treatment. Dermatol Ther. 2010; 23(3):220-9.
• [19]McCullough MJ, Tyas MJ. Local adverse effects of amalgam restorations. Int Dent J. 2008; 58(1):3-9.
• [20]Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol. 2000; 18:579-87.
• [21]Mergoni G, Ergun S, Vescovi P, Mete O, Tanyeri H, Meleti M. Oralpostinflammatory pigmentation: an analysis of 7 cases. Med Oral Patol Oral Cir Bucal. 2011; 16(1):e11-4.
• [22]Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(6):718-25.
• [23]Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy. Newly approved and developmental agents. CNS Drugs. 2011; 25:89-107.
• [24]Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012; 53(3):412-24.
• [25]European Medicines Agency. 2013. European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy Procedure No.EMEA/H/C/001245. EMA, London. 20 January 2011. http://www. ema.europa.eu/docs/en_GB/document_library/Press_release/human/001245/WC500143799.pdf. webcite
• [26]Prescott J, Evans C, Saenz AA. 2014. Pigmentary abnormalities (discolouration) associated with exogabine/retigabine treatment: non clinical aspects. Presented at American Epilepsy Society, Seattle, Washington, USA, 5-9th December.